VYNE Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.135 million compared to USD 0.126 million a year ago. Net loss was USD 10.06 million compared to USD 8.48 million a year ago. Basic loss per share from continuing operations was USD 3.08 compared to USD 2.56 a year ago. Basic loss per share was USD 3.09 compared to USD 2.63 a year ago.
For the six months, revenue was USD 0.234 million compared to USD 0.304 million a year ago. Net loss was USD 15.68 million compared to USD 3.81 million a year ago. Basic loss per share from continuing operations was USD 4.81 compared to USD 5.38 a year ago. Basic loss per share was USD 4.82 compared to USD 1.21 a year ago.